Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MS analsysis of phosphoproteins separated by phos-tag diagonal electrophoresis of yeast 26S proteasome

ABSTRACT: Phosphorylation status of yeast 26S proteasome subunits was analyzed by phos-tag diagonal electrophoresis and GeLC-MS analysis.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Hisashi Hirano

PROVIDER: PXD020706 | JPOST Repository | Tue Aug 03 00:00:00 BST 2021

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Similar Datasets

MS analsysis of phosphoproteins separated by phos-tag diagonal electrophoresis of Human 26S proteasome

Project description:Phosphorylation status of human 26S proteasome subunits was analyzed by phos-tag diagonal electrophoresis and GeLC-MS analysis.

2021-08-03 | PXD020705 | JPOST Repository

Activity guided profiling of yeast proteasome - protein extraction test

Project description:This experiment compared the impact of protein extraction conditions on the identification and quantification of proteasome subunits in WT yeast. It involved comparing proteins extracted from identical WT yeast samples under two different conditions: native and denaturing (in the presence of SDS and TCA).

2024-02-15 | PXD048380 | Pride

Proteasome Function is Required for Platelet Production

Project description:RNA-seq expression analysis of transcripts encoding proteasome subunits in human CD34+ cord blood cell-derived megakaryocytes and mouse bone marrow-derived megakaryocytes.

2015-01-31 | GSE58202 | GEO

Proteasome Function is Required for Platelet Production

Project description:RNA-seq expression analysis of transcripts encoding proteasome subunits in human CD34+ cord blood cell-derived megakaryocytes and mouse bone marrow-derived megakaryocytes. Analysis of transcript expression in human CD34+ cord blood cell-derived megakaryocytes and mouse bone marrow-derived megakaryocytes.

2015-01-31 | E-GEOD-58202 | biostudies-arrayexpress

Synergistic effects of TOR and proteasome pathways on the yeast transcriptome and cell growth

Project description:The experiments were designed to interrogate the genetic interaction relationship between the TOR signalling pathway and the UPS-proteasome pathway in gene expression and cell growth. Yeast cells (BY4742pdr5delta) were treated with the drug vehicle, MG132 (50uM), rapamycin (200ng/ml) or both drugs. Samples in triplicates were taken at 0, 1, 2 and 3hours after treatment. Transcriptome were assayed using Affimetrixs genechips (Yeast 2).

2013-05-24 | E-MTAB-1550 | biostudies-arrayexpress

Proteasome gene expression is controlled by the coordinated functions of multiple transcription factors

Project description:Proteasome activity is crucial for cellular integrity, but how tissues adjust proteasome content in response to catabolic stimuli is uncertain. Here, we demonstrate that transcriptional coordination by multiple transcription factors is required to increase proteasome content and activate proteolysis in catabolic states. Using denervated mouse muscle as a model system for accelerated proteolysis in vivo, we reveal that a two-phase transcriptional program activates genes encoding proteasome subunits and assembly chaperones to boost an increase in proteasome content. Initially, gene induction is necessary to maintain basal proteasome levels, and in a more delayed phase (7-10 d after denervation) it stimulates proteasome assembly to meet cellular demand for excessive proteolysis. Intriguingly, the transcription factors PAX4 and α-PALNRF-1 control the expression of proteasome among other genes in a combinatorial manner, driving cellular adaptation to muscle denervation. Consequently, PAX4 and α-PALNRF-1 represent new therapeutic targets to inhibit proteolysis in catabolic diseases (e.g. type-2 diabetes, cancer).

2024-05-01 | GSE232348 | GEO

Tagging the proteasome active site ?5 causes tag specific phenotypes in yeast.

Project description: Not available

| S-EPMC7582879 | biostudies-literature

Absolute quantification of proteasome subunits

Project description:we prepared synthetic proteins corresponding to 30 of the proteasome subunits by stable isotope labeling and then performed absolute quantification.

2020-11-13 | PXD016260 | JPOST Repository

Tight Junction Protein 1 is a Modulator and Biomarker of Proteasome Inhibitor Sensitivity in Multiple Myeloma

Project description:Proteasome inhibitors are important chemotherapeutics in the treatment of multiple myeloma, but they are currently used empirically as no markers of sensitivity have been validated. We have identified expression of tight junction protein (TJP) 1 as being associated with sensitivity of plasma cells in vitro and in vivo to proteasome inhibitors. TJP1 suppressed expression of genes in the major histocompatibility class II region, including two catalytically active immunoproteasome subunits, thereby decreasing proteasome activity, a critical determinant of proteasome inhibitor sensitivity. This occurred through suppression by TJP1 of signaling through the epidermal growth factor receptor/Janus kinase 1/signal transducer and activator of transcription 3 pathway. In the clinic, high TJP1 expression in myeloma patients was associated with a significantly higher likelihood of responding to bortezomib, and with a longer time-to-progression after treatment. Taken together, these data support the use of TJP1 as a biomarker of sensitivity and resistance to proteasome inhibitors. To further elucidate mechanisms of bortezomib resistance, we developed human-derived multiple myeloma cell lines with a 4-fold or greater resistance to bortezomib. Then total RNA for bortezomib resistant (BR) and wild type (WT) was extracted and used for comparison by gene expression profiling.

2015-12-31 | E-GEOD-52369 | biostudies-arrayexpress

siRNA of human MCF7 cells incubated with proteasome inhibitors bortezomib or Argyrin A or proteasome activity and knocked down for proteosomal subunits

Project description:Reduction in the cellular levels of the cyclin kinase inhibitor p27kip1 are frequently found in many human cancers and correlate directly with patient prognosis. Specifically ubiquitin dependent proteasomal turnover has been shown to cause reduced p27 expression in many human cancers. We recently demonstated that expression of a stabilized version of p27kip1 (p27kip1T187A) in a genetically modified mouse significantly reduced the number of intestinal adenomatous polyps which progressed to invasive carcinomas. Based on this work we set out to identify compounds which lead to a re-expression of p27 in cancer tissues. In this work we identify Argyrin A a compound derived from myxobacterium archangium gephyra as a potent inducer of p27kip1 expression. Argyrin A induces apoptosis in human colon cancer xenografts and tumor vasculature in vivo leading to a profound reduction in tumor size at well tolerated levels. Argyrin A functions are strictly dependent on the expression of p27kip1 as neither tumor cells nor endothelial cells which do not express p27kip1 respond to this compound. Surprisingly the molecular mechanism by which Argyrin A exerts its p27 dependent biological function is through a potent inhibition of the 20S proteasome. Experiment Overall Design: MCF7 cells were incubated with proteasome inhibitors bortezomib or Argyrin A or proteasome activity was reduced by treatment with siRNA against proteasomal subunits and gene expression profiles were determined at different timepoints thereafter.

2008-06-16 | E-GEOD-8565 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data